(357) Microfluidics Manufacturing of Liposomal Adjuvants
Introduction: Liposomes are versatile carriers for drugs and vaccines. Cationic liposomes, composed of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and dimethyldioctadecylammonium (bromide salt) (DDAB), have demonstrated stability and compatibility with the vaccine platform (1). In addition, Cyclic di-adenosine monophosphate (CDA) has shown the potential to be a promising adjuvant in developing vaccines (2). This study tested the ability to manufacture novel cationic liposomal adjuvants using microfluidics technology.
Learning Objectives:
Understand how TFR and FRR affect liposome size and zeta potential.
Explore how the DDAB ratio affects liposome size and zeta potential.
Learn the method of conjugating CDA with DDAB-containing liposomes.
